Tony Fiorino, MD, PhD

Interim Chief Executive Officer

Dr. Fiorino was appointed Immune’s Interim CEO in August 2018. He joined the Company as CMO and COO in August 2017 from Triumvira Immunologics, an immuno-oncology company developing a novel engineered T cell platform, where he served as President and Chief Executive Officer. Prior to joining Triumvira, Dr. Fiorino was the Chief Executive Officer of BrainStorm Cell Therapeutics (NASDAQ: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases. During his tenure, BrainStorm conducted a phase 2 trial of neurotrophic factor-secreting mesenchymal stem cells in amyotrophic lateral sclerosis, raised $25 million in equity capital, and uplisted to the NASDAQ. Prior to joining BrainStorm, he was the Founder, President and CEO of EnzymeRx, where he led the acquisition of a late-stage pre-clinical biologic and the development of the compound through phase 2 clinical trials and its subsequent sale to 3SBio. Before founding EnzymeRx, Dr. Fiorino worked as a biotechnology and pharmaceuticals analyst and portfolio manager at firms including JP Morgan, Citigroup, and Pequot Capital. Dr. Fiorino earned an MD and a PhD from the Albert Einstein College of Medicine, where he studied the differentiation of liver progenitor cells, and a BS from the Massachusetts Institute of Technology.

Elliot Maza, JD, CPA

Chief Executive Officer

Elliot Maza was appointed Chief Executive Officer of Immune Pharmaceuticals in September 2017, after serving in this capacity on an interim basis since April 2017 and as a Director since January 2015.  Previously he was Chairman, Chief Executive Officer and Chief Financial Officer at Intellect Neurosciences, Inc.,  Chief Executive Officer and Chief Financial Officer at Biozone Pharmaceuticals, Inc. and Chief Financial Officer of Emisphere Technologies Inc. Elliot was a Partner, Transaction Advisory Services, at Ernst & Young, LLP. He began his professional career as an Attorney at Sullivan and Cromwell in New York and then in Investment banking as Vice President of Structured Finance in the Fixed Income divisions of Goldman Sachs & Co. and J.P. Morgan Securities, Inc., where he developed and marketed structured finance and derivative based transactions. Elliot has served on numerous Boards of Directors for OTC and NASDAQ traded companies, including positions as Chairman of the Audit Committee. He is a registered attorney and a licensed C.P.A. (inactive) in the states of New York and New Jersey. He received a B.A. in Accounting from Touro College in New York and a J.D. from the University of Pennsylvania Law School.

John Zhang, MD, PhD

Vice President, Research and Development

Dr. Zhang has more than 20 years of experience in preclinical and early clinical drug development in the pharmaceutical and biotech industries. His professional expertise is in the areas of toxicology, pharmacology, drug metabolism and pharmacokinetics, animal efficacy models, and early clinical studies. He has led preclinical project teams across various stages of drug development, from drug candidate selection to late stage clinical studies and product cycle management. John planned and executed preclinical programs for both biologics and small molecules and has participated in the successful filings of more than 14 INDs, 5 NDAs/BLAs and 3 MAAs in the therapeutic areas of oncology, immuno-oncology, and inflammation. Dr. Zhang earned a medical degree from Guangxi Medical University, Nanning, China; an MS from the UCLA School of Public Health, a PhD in toxicology from Rutgers University/UMDNJ and completed his postdoctoral training at the National Institutes of Health.